Cardiometabolism and Interorgan Crosstalk: Novel Mechanisms and Therapies
Feb 16–19, 2027 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Saptarsi M. Haldar, Karol E. Watson, and David A Kass
×
-
Feb 16–19, 2027 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Saptarsi M. Haldar, Karol E. Watson, and David A Kass
Saptarsi M. Haldar, MD
Genentech / Roche
Saptarsi Haldar, M.D. is a physician-scientist and Senior Vice President and Global Head of Research Biology at Genentech, and a visiting professor at the Gladstone Institutes and University of California San Francisco. He oversees research programs spanning oncology, immunology, neurology, cardiovascular/metabolic/renal, ophthalmology, infectious disease, human genetics, functional genomics and proteomics discovery platforms. Previously, he was head of Cardiovascular/Metabolic and Rare Disease Therapeutics at Amgen. He served as faculty at Case Western Reserve School of Medicine, Gladstone Institutes and UCSF, where his lab uncovered novel gene regulatory signaling mechanisms governing cardiovascular and metabolic homeostasis.
Karol E. Watson, MD
University of California, Los Angeles
Karol Watson, MD, PhD is a board-certified cardiologist and vascular biologist with specialized training in clinical investigation and epidemiology. She completed a residency in Internal Medicine and a fellowship in Cardiology at UCLA and continued there as part of the UCLA Specialty Training and Academic Research program and as Chief Fellow in Cardiovascular Diseases. Dr. Watson currently co-leads Big Data research at UCLA’s Heart BD2K Center with Dr. PeiPei Ping, and her clinical and epidemiology work focuses on cardiovascular disease in populations affected by health disparities.
David A Kass, MD
Johns Hopkins Hospital
David A. Kass, M.D., is the Abraham and Virginia Weiss Professor of Cardiology and Professor of Medicine and Biomedical Engineering at the Johns Hopkins University School of medicine. His research spans integrative physiology, the biomechanics of heart disease in both human and large-animal models, and the molecular and cellular biology of heart failure and therapeutic development. He played a major role in developing cardiac resynchronization therapy and uncovering mechanisms and therapeutic applications for cardiac cGMP/PKG activation through selective phosphodiesterase inhibition. His recent work focuses on heart failure with preserved ejection fraction and effects of morbid obesity on myocyte and sarcomere biomechanics and metabolic signaling, informed by human myocardial tissue data from HFpEF patients. Dr. Kass has extensive experience in organizing national and international conferences including Gordon, Keystone, and American Heart Association meetings.
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandTuesday, February 16, 2027
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
1:00–6:00 PM
Colorado Ballroom Foyer
Welcome Remarks
3:00–3:10 PM
Colorado Ballroom Peak 4-5
Keynote Address
3:10–4:00 PM
Colorado Ballroom Peak 4-5
Daniel J. Drucker, Lunenfeld-Tanenbaum Research Institute
Mechanisms of Incretin Therapy and their CV and Neurological Benefits
Mechanisms of Incretin Therapy and their CV and Neurological Benefits
Nervous System Crosstalk in Cardiometabolic Disease
4:00–6:00 PM
Colorado Ballroom Peak 4-5
Ana Domingos, University of Oxford
Sympathetic Neural Circuits Burning Fat
Sympathetic Neural Circuits Burning Fat
Daniela Carnevale, University La Sapienza in Rome
Heart-Brain-Splenic Axis and Control of Cardiovascular Disease
Heart-Brain-Splenic Axis and Control of Cardiovascular Disease
Filip K. Swirski, Icahn School of Medicine at Mount Sinai
Novel Immune/Neural Mechanisms in Cardiometabolic Disease
Novel Immune/Neural Mechanisms in Cardiometabolic Disease
Sophie M Steculorum, Max Planck Institute for Metabolism Research
Sensory Regulation of Metabolism
Sensory Regulation of Metabolism
Welcome Mixer with Heavy Apps
6:00–8:00 PM
Colorado Ballroom Foyer
Wednesday, February 17, 2027
Breakfast
7:00–8:00 AM
Summit Gallery
Skeletal Muscle and Vascular Crosstalk and CV Disease
8:00–11:00 AM
Colorado Ballroom Peak 4-5
Zoltan Arany, University of Pennsylvania
Rerouting Metabolic Fuel Flux Utilization across Organs in Cardiometabolic Disease
Rerouting Metabolic Fuel Flux Utilization across Organs in Cardiometabolic Disease
Flora Sam, Eli Lilly
Skeletal Muscle Myokines and HFpEF
Skeletal Muscle Myokines and HFpEF
Kristin I. Stanford, Ohio State University
Exercise, Adipose & Metabolic Crosstalk
Exercise, Adipose & Metabolic Crosstalk
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Panel Discussion: AI Tools in Cardiometabolic Research
11:10–12:10 PM
Colorado Ballroom Peak 4-5
Poster Setup
12:10–1:00 PM
Colorado Ballroom Peak 1-3
On Own for Lunch
12:10–3:00 PM
Poster Viewing
1:00–10:00 PM
Colorado Ballroom Peak 1-3
Career Roundtable
3:00–4:30 PM
Colorado Ballroom Peak 4-5
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Immune-Renal-Cardiac Crosstalk
5:00–7:00 PM
Colorado Ballroom Peak 4-5
Kory J. Lavine, Washington University School of Medicine
Single Cell Epigenomics to Reveal Cellular Crosstalk in CV Disease
Single Cell Epigenomics to Reveal Cellular Crosstalk in CV Disease
Pilar Alcaide, University of Miami - Miller School of Medicine
T Cells Modulation of Cardiac Stiffening in Cardiometabolic HFpEF
T Cells Modulation of Cardiac Stiffening in Cardiometabolic HFpEF
Susmita Sahoo, Icahn School of Medicine at Mount Sinai
Kidney-to-Heart Communication: Kidney-Derived EV-miRNAs as A Diagnostic Tool for Subclinical Heart Disease in CKD
Kidney-to-Heart Communication: Kidney-Derived EV-miRNAs as A Diagnostic Tool for Subclinical Heart Disease in CKD
Han Zhu, Stanford University
T Lymphocyte Subsets in Cardiovascular Homeostasis and Response to Cancer Immunotherapy
T Lymphocyte Subsets in Cardiovascular Homeostasis and Response to Cancer Immunotherapy
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 1
7:30–10:00 PM
Colorado Ballroom Peak 1-3
Thursday, February 18, 2027
Breakfast
7:00–8:00 AM
Summit Gallery
Emerging Cardiometabolic Therapeutics
8:00–11:00 AM
Colorado Ballroom Peak 4-5
William A. Chutkow, Novartis Institute for Biomedical Research
Targeting Lean Muscle Mass in Cardiovascular and Metabolic Disease
Targeting Lean Muscle Mass in Cardiovascular and Metabolic Disease
Ambarish Pandey, UT Southwestern Medical Center
Heterogeneity in the Cardiovascular Benefits of GLP-1R Agonists: Identifying Treatment Responders Leveraging Novel Phenotyping and Data Science Approach
Heterogeneity in the Cardiovascular Benefits of GLP-1R Agonists: Identifying Treatment Responders Leveraging Novel Phenotyping and Data Science Approach
Jori Chambers, Souffle Therapeutics
Myocyte Selective Gene Silencing for the Treatment of Heart Disease
Myocyte Selective Gene Silencing for the Treatment of Heart Disease
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Award Recipient Acknowledgement
9:20–9:25 AM
Colorado Ballroom Peak 4-5
Poster Setup
11:00–1:00 PM
Colorado Ballroom Peak 1-3
On Own for Lunch
11:00–2:30 PM
Poster Viewing
11:00–10:00 PM
Colorado Ballroom Peak 1-3
Symposia Spotlight 1
2:30–4:30 PM
Colorado Ballroom Peak 4-5
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Target Discovery and Patient Segmentation in Cardiometabolic Disease: AI and Human Genetics
5:00–7:00 PM
Colorado Ballroom Peak 4-5
Luca Lotta, Regeneron Pharmaceuticals Inc.
Human Genetics at the Intersection of Metabolism and CV Risk
Human Genetics at the Intersection of Metabolism and CV Risk
Rajat Gupta, Massachusetts General Hospital
Functional Genomics and Perturbational Screening for Cardiometabolic Target Discovery
Functional Genomics and Perturbational Screening for Cardiometabolic Target Discovery
Anna Helgadottir, deCODE genetics
Metabolic Drivers of CVD and Implications for Clinical Trial Enrichment
Metabolic Drivers of CVD and Implications for Clinical Trial Enrichment
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 2
7:30–10:00 PM
Colorado Ballroom Peak 1-3
Friday, February 19, 2027
Breakfast
7:00–8:00 PM
Summit Gallery
Adiposity, Diabetes and Clinical CV Disease
8:00–11:00 PM
David A Kass, Johns Hopkins Hospital
Obesity + HFpEF = Bad Sarcomeres
Obesity + HFpEF = Bad Sarcomeres
Karol E. Watson, University of California, Los Angeles
Novel Insights from the DPPOS Cohort
Novel Insights from the DPPOS Cohort
Saptarsi M. Haldar, Genentech / Roche
Novel Approaches to Treating Obesity and Adiposity-Related Diseases
Novel Approaches to Treating Obesity and Adiposity-Related Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 PM
Colorado Ballroom Foyer
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Novel Mechanisms of Liver, Adipose and Cardiovascular Crosstalk
5:00–7:00 PM
Isha Jain, Arc Institute and Gladstone/UCSF
Hypoxic Signaling and Interorgan Crosstalk in Physiology & Disease
Hypoxic Signaling and Interorgan Crosstalk in Physiology & Disease
E. Dale Abel, David Geffen School of Medicine and UCLA Health
Insulin Signaling, Mitochondria and Metabolic Heart Disease
Insulin Signaling, Mitochondria and Metabolic Heart Disease
Katrin J. Svensson, Stanford University
Novel Peptides as Obesity Therapeutic Targets
Novel Peptides as Obesity Therapeutic Targets
Gabriele G Schiattarella, Charité University Medical Center
Cardiometabolic-Hepatic Crosstalk
Cardiometabolic-Hepatic Crosstalk
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Colorado Ballroom Peak 4-5
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Cash Bar
8:00–9:00 PM
Colorado Ballroom Peak 1-3
Entertainment
8:00–9:00 PM
Colorado Ballroom Peak 1-3
Saturday, February 20, 2027
Departure
12:00–11:59 PM
Subscribe for Updates